SCHEMBL15420189

SCHEMBL15420189

CCS(=O)(=O)NC1CCOCC1COc1ccc(-n2nccc2C)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 1/20 0.34
CYP2C9 P11712 1/20 0.33
ACACB O00763 3/20 0.31
EIF2AK4 Q9P2K8 1/20 0.31
LMNA P02545 2/20 0.31
GAA P10253 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
MAPT P10636 1/20 0.31
HTT P42858 1/20 0.31
KMT2A Q03164 1/20 0.31
FPR1 P21462 1/20 0.31
ALDH1A1 P00352 2/20 0.31
GLA P06280 1/20 0.31
FFAR4 Q5NUL3 1/20 0.30
BRD4 O60885 1/20 0.30
HRH3 Q9Y5N1 1/20 0.30
POLB P06746 1/20 0.30
PDE1A P54750 1/20 0.30
PDE1B Q01064 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15441865 1.00 ADAM17 (0.34) ADAM17CYP2C9ACACBEIF2AK4LMNA
SCHEMBL15420452 0.87 FFAR4 (0.38) ADAM17LMNAKDM4EMEN1MAPT
SCHEMBL15420456 0.87 FFAR4 (0.38) ADAM17LMNAKDM4EMEN1MAPT
SCHEMBL15420453 0.87 FFAR4 (0.38) ADAM17LMNAKDM4EMEN1MAPT
SCHEMBL12988723 0.84 CHRM1 (0.42) MEN1MAPTKMT2AHRH3
SCHEMBL12988721 0.84 CHRM1 (0.42) MEN1MAPTKMT2AHRH3
SCHEMBL12988718 0.84 CHRM1 (0.42) MEN1MAPTKMT2AHRH3
SCHEMBL15420129 0.83 KAT5 (0.38) ADAM17ACACBEIF2AK4HRH3IDH1
SCHEMBL15419964 0.83 KAT5 (0.38) ADAM17ACACBEIF2AK4HRH3IDH1
SCHEMBL15420102 0.83 KAT5 (0.38) ADAM17ACACBEIF2AK4HRH3IDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694472-B1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2020-03-11 EP disclosed
US-9527807-B2 Sulfonamide derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-12-27 US disclosed
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140024650-A1 SULFONAMIDE DERIVATIVE AND USE THEREOF GRIN2A, GRIN2B, SLC1A2 ADAM17 1833/4885CYP2C9 2080/4885ACACB 3123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.